#DELFI is excited to support the GO2 for Lung Centers of Excellence Summit, Sept 30-Oct 2 at the InterContinental Chicago. DELFI Account Executives Allyson Perdue and Kevin Torres will attend this annual, multiday event that attracts lung cancer professionals nationwide. Renowned lung cancer experts share cutting-edge technologies, emerging therapies, and the successes and challenges of program implementation. This year's theme is ""Building Safe and Sound Intersections: Partnering to Transform Lung Cancer."" The conference agenda can be reviewed here: https://lnkd.in/e6y__rXS
DELFI Diagnostics
Biotechnology Research
Baltimore, Maryland 15,152 followers
Saving lives through early cancer detection
About us
DELFI uses artificial intelligence and whole genome sequencing to sensitively detect unique patterns of DNA fragmentation in the blood of patients with cancer.
- Website
-
http://www.delfidiagnostics.com
External link for DELFI Diagnostics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Baltimore, Maryland
- Type
- Privately Held
- Founded
- 2019
Locations
-
Primary
2809 Boston St
Suite 503
Baltimore, Maryland 21224, US
Employees at DELFI Diagnostics
Updates
-
#ICYMI Today closes #WCLC24 in San Diego, at which #DELFI Director of Medical Affairs, Dr. Lindsey C., presented 2 posters on our blood-based test to enhance #lungcancer detection. The two posters presented: P2.04A.01 FIRSTLUNG (L301): Cluster Randomized Trial Evaluating the Clinical Utility of DELFI's Blood-Based Lung Cancer Screening Test- https://bit.ly/3Mxe1mE P4.04C.07: Improving the Efficiency of Lung Cancer Screening Through a Blood-based Lung Cancer Screening Test Prior to Low-Dose CT - https://bit.ly/47f9Yov We thank Dr. Cotton and the organizers for the opportunity to discuss the potential to change the lung cancer detection landscape. #cancerresearch #lungcancer #cancerscreening #healthsystems #healthcaresystems #liquidbiopsy
-
#DELFI returns to the #WCLC24 in San Diego! Director of Medical Affairs, Lindsey C., will present a poster today, her second of this conference. The poster, P4.04C.07, is titled: "Improving the Efficiency of Lung Cancer Screening Through a Blood-based Lung Cancer Screening Test Prior to Low-Dose CT." The abstract is accessible here: https://bit.ly/47f9Yov Widescale lung cancer screening to detect early lung cancer with low-dose computed tomography (LDCT) can strain already taxed health systems. We evaluated whether initially evaluating screen-eligible individuals with an accessible blood-based screening test could reduce the burden of lung cancer screening without minimizing cancer detection. #cancerresearch #cancerscreening #liquidbiopsy #lungcancerscreening #lungcancer #lungcancerresearch
-
DELFI is live at #WCLC24 in San Diego! Our Director of Medical Affairs, Dr. Lindsey C. will present a poster today, one of two DELFI abstracts being shared at this conference. Entitled "P2.04A.01 FIRSTLUNG (L301): Cluster Randomized Trial Evaluating the Clinical Utility of DELFI's Blood-Based Lung Cancer Screening Test", this abstract provides an overview of the L301 trial (NCT06145750), a prospective, randomized, controlled trial to observe the impact of the DELFI #lungcancer screening test in primary care practices. We are delighted to announce that in the same poster session, Loretta Erhunmwunsee, MD of City of Hope, will present a poster entitled "P2.04A.08 Feasibility of Cell-Free DNA Liquid Biopsy in Screening High-Risk Patients for Lung Cancer." The poster details the investigator-led study led by Dan Raz, MD at City of Hope that will evaluate the FirstLook Test to improve lung cancer screening rates in under-resourced communities in the Los Angeles area. #cancerresearch #cancerscreening #liquidbiopsy Click here for more details on the poster session: https://lnkd.in/ePJGHztE
-
Attending Northwestern University - The Feinberg School of Medicine's Lung Cancer Symposium in Chicago on Friday, Sept. 6? Come meet Kevin Torres of the #DELFI Key Accounts Partnership team at the DELFI booth. We're delighted to be exhibiting at the Annual Northwestern Medicine Respiratory and Critical Care Symposium, which brings together experts in #pulmonarymedicine, #criticalcaremedicine, and #thoracicsurgery to discuss #evidencebased updates. The Symposium's objectives are to: - Describe and apply a multidisciplinary approach to #lungcancerdiagnosis and management - Examine the role of targeted #biologictherapies in the management of lung cancer - Demonstrate knowledge about the criteria for diagnosis and treatment of lung cancer Join us for this one-day event and participate in critical conversations about the detection, treatment, and management of lung cancer! To learn more or register: https://bit.ly/4e9daEh
-
#DELFI is preparing to attend the #WCLC24 in San Diego, held September 7-10. Our Director of Medical Affairs, Dr. Lindsey C., will present two posters: Sunday, 9/8: "P2.04A.01 FIRSTLUNG (L301): Cluster Randomized Trial Evaluating the Clinical Utility of DELFI's Blood-Based Lung Cancer Screening Test" - https://lnkd.in/ePJGHztE Monday, 9/9: "P4.04C.07: Improving the Efficiency of Lung Cancer Screening Through a Blood-based Lung Cancer Screening Test Prior to Low-Dose CT" - https://lnkd.in/eesEbApA Other members of the DELFI team will attend #WCLC24 including Account Executives Allyson Perdue and Patra Glavin, VP of Market Access & Health Economics Chris Cisar, Medical Science Liaison Dr. Demetria Tennefoss and CMO Peter B.. If you want to learn more about partnering with DELFI to enhance lung cancer screening in your #healthsystem, please contact Allyson Perdue to schedule a meeting. #cancerresearch #lungcancer #cancerscreening #healthsystems #healthcaresystems #liquidbiopsy
-
Congratulations to #DELFI founder Victor Velculescu and his academic colleagues on publishing a new paper in Nature Communications! The paper, "DNA methylation and gene expression as determinants of genome-wide cell-free DNA fragmentation," establishes a connection between epigenetic changes and cfDNA fragmentation with implications for disease detection. Based on an analysis of 969 individuals, the findings underscore the effectiveness of DELFI's cfDNA assay, which employs a genome-wide fragmentomic-based approach to aid early #lungcancer detection. The paper is co-authored by Dr. Velculescu, Michaël Noë and colleagues at The Johns Hopkins University School of Medicine. Read the full article: https://lnkd.in/e-SCBzbb #cancerresearch #cfDNA #fragmentomics #JHU
-
Breaking news! We are thrilled and proud to announce that #DELFI Bioinformatics Scientist Bahar Alipanahi has been selected to present an abstract at The Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting, on November 9 in Houston, Texas. Dr. Alipanahi's presentation will review the progress of monitoring #immunotherapy response in #lungcancer via cell-free DNA #fragmentomics. What are cfDNA fragmentomes? In short, these fragments are the remnants of cancer cells that shed DNA into the bloodstream. Abnormal fragment patterns can indicate the possible presence of #cancer. To find out more about Society for Immunotherapy of Cancer (SITC), visit: https://bit.ly/3WRUe5Y #cancertreatment #cancerscreening #earlydetection #cancerresearch #SITC24
-
Thank you to 360Dx for sharing news of Tom Russo's appointment to CFO at #DELFI. https://lnkd.in/ghmB7hkB
-
#DELFI is excited to welcome our new CFO Tom Russo! His financial, investor, and biopharma operations expertise, and proven track record of supporting #healthcare #innovation, will be invaluable to DELFI's growth and commitment to the #earlydetection of cancer. Tom Russo most recently served as CFO of Icosavax, Inc., where he helped guide the clinical-stage biopharmaceutical company through a pivotal growth period that led to its acquisition by AstraZeneca for up to $1.1B. At DELFI, Tom will help drive the company’s expansion into the blood-based #liquidbiopsy market with the #FirstLook Lung test. https://lnkd.in/ekauwCr5 #newCFO #welcome #leadershipteam